A recall of Losartan potassium tablets that could contain a cancer-causing impurity was expanded Thursday to include more lots. It's the second recall of its kind this week and one of several since ...
The number doctors use to demarcate hypertension keeps going down, a trend applauded by many experts, who point to studies ...
New drug, baxdrostat, significantly lowered high blood pressure in patients resistant to standard treatments in a phase III clinical trial. The corresponding study was published in the New England ...
A new analysis shows the 2025 hypertension guideline’s risk-based framework spares a small subgroup from immediate treatment.
SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood pressure, fasting glucose, and weight for patients with adrenal ...
The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in ...
Hosted on MSN
More Than 580,000 Blood Pressure Drugs Recalled Nationwide for Possible Cancer-Causing Impurities
A new recall affecting more than 580,000 bottles of blood pressure medication may give patients pause as they weigh concerns about medication safety against managing their condition. The recall comes ...
The FDA accepts the NDA for lorundrostat, a selective aldosterone synthase inhibitor, for adults with uncontrolled or resistant hypertension.
A new drug that significantly lowers "stubborn" blood pressure is on the horizon, following the results of its Phase III clinical trial. The treatment, called baxdrostat, has been hailed as the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results